Vipoglanstat not checked
Gesynta Pharma AB · GS-248
FollowEvery change as it happens, and a Monday email
Trials
1 active
4 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period.”In the company’s words, NCT07260669 on ClinicalTrials.gov
- Tested for
- Endometriosis
- Main trialPhase 2
- “The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).”In the company’s words, NCT07260669 on ClinicalTrials.gov
- Other names
- GS-248
Other drugs for Endometriosis
- ElagolixAbbVie · Phase 3
- LinzagolixKissei Pharmaceutical Co., Ltd. · Phase 3
- HMI-115Hope Medicine (Nanjing) Co., Ltd · Phase 3
- RelugolixSumitomo Pharma America, Inc. · Phase 3
- Teverelix DPAntev Ltd. · Phase 2
- HHK001Huahai Pharmaceutical (Huaota) · Phase 1
Coming up1
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Jun 2027 | A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis | |
| Phase 2Completed | 15 Jun 2022 | A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis | |
| Phase 1Completed | 20 Dec 2019 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248 | |
| Phase 1Completed | 27 May 2020 | A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026